LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Search

Codexis Inc

Cerrado

SectorSanidad

2.4 -0.41

Resumen

Variación precio

24h

Actual

Mínimo

2.4

Máximo

2.42

Métricas clave

By Trading Economics

Ingresos

-18M

-8.7M

Ventas

-24M

15M

BPA

-0.1

Margen de beneficios

-57.083

Empleados

146

EBITDA

-23M

-5.8M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+187.5% upside

Dividendos

By Acuity

Próximas Ganancias

12 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8.6M

237M

Apertura anterior

2.81

Cierre anterior

2.4

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

48 / 342 Clasificación en Healthcare

Codexis Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Acerca de Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat